632eP Prevalence of ESR1 mutations in ER+/HER2- advanced breast cancer (aBC) patients treated with everolimus after CDK4/6 inhibitors

François C. Bocquet, Alice Rudolph, P Cottu et al.|Annals of Oncology|2025

Cited by 0